Literature DB >> 18237767

Thromboembolism in children with lymphoma.

Uma H Athale1, Kim Nagel, Anees A Khan, Anthony K C Chan.   

Abstract

PURPOSE: Cancer is a major underlying disease in children with thromboembolism. However, the epidemiology of thrombosis in children with cancer is largely unknown. We undertook the following study to define the epidemiology and to identify the risk factors predisposing children with lymphoma to thrombosis. PATIENTS AND METHODS: We reviewed the medical records of 75 children (<18 years of age) diagnosed with lymphoma from January 1990-December 2004.
RESULTS: Nine of 75 patients (12%, 95% CI; 5.6-21.6%) were diagnosed with a total of 16 thrombotic events. Twelve of 16 (75%) events were venous thrombosis; 11 were related to the central venous line. The prevalence of pulmonary embolism was 2.6%. Nine of 51 (17.6%) patients with mediastinal lymphadenopathy developed thrombosis compared to none of 21 patients without mediastinal lymphadenopathy (Z=3.31, p=0.001, 95%CI; 7.2-28.1%). Older children and children with advanced stage disease were at higher, but statistically non-significant risk of thrombosis. There was no effect of gender, lymphoma type, or B-symptoms on the occurrence of thrombosis. Four of 9 patients (44%) experienced recurrent clots and 3 (33.3%) patients had post-thrombotic syndrome. Children with thrombosis had a higher rate of adverse events compared to those without thrombosis (41% vs. 21.2%, p=0.126).
CONCLUSION: Thrombosis is a frequent complication in children with lymphoma with over a 40% recurrence rate and significant morbidity. Children with a mediastinal mass were at significantly increased risk of thrombosis. Larger prospective studies are required to confirm these findings and to identify children at an increased risk for the development of thrombosis.

Entities:  

Mesh:

Year:  2008        PMID: 18237767     DOI: 10.1016/j.thromres.2007.12.006

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors.

Authors:  Neil A Goldenberg; Marco P Donadini; Susan R Kahn; Mark Crowther; Gili Kenet; Ulrike Nowak-Göttl; Marilyn J Manco-Johnson
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

3.  The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas.

Authors:  Jessica Gartrell; Sue C Kaste; John T Sandlund; Jamie Flerlage; Yinmei Zhou; Cheng Cheng; Jeremie Estepp; Monika L Metzger
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

Review 4.  Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Authors:  Anna Falanga; Benjamin Brenner; Alok A Khorana; Charles W Francis
Journal:  Res Pract Thromb Haemost       Date:  2022-07-01

5.  Venous thromboembolism in children with cancer - a population-based cohort study.

Authors:  Alex J Walker; Matthew J Grainge; Tim R Card; Joe West; Susanna Ranta; Jonas F Ludvigsson
Journal:  Thromb Res       Date:  2013-12-21       Impact factor: 3.944

Review 6.  Venous Thromboembolism in Children with Cancer and Blood Disorders.

Authors:  Richard H Ko; Courtney D Thornburg
Journal:  Front Pediatr       Date:  2017-02-06       Impact factor: 3.418

7.  Central venous catheter-associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice.

Authors:  Ceder H van den Bosch; Judith Spijkerman; Marc H W A Wijnen; Idske C L Kremer Hovinga; Friederike A G Meyer-Wentrup; Alida F W van der Steeg; Marianne D van de Wetering; Marta Fiocco; Indra E Morsing; Auke Beishuizen
Journal:  Support Care Cancer       Date:  2022-07-01       Impact factor: 3.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.